vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and Village Farms International, Inc. (VFF). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $12.2M, roughly 1.6× Village Farms International, Inc.). Village Farms International, Inc. runs the higher net margin — 19.9% vs -177.4%, a 197.3% gap on every dollar of revenue. On growth, Village Farms International, Inc. posted the faster year-over-year revenue change (31.5% vs -11.5%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

Grafton Village Cheese Company is a cheesemaker in the town of Grafton in the U.S. state of Vermont. The company produces hand-crafted aged cheddar cheese.

LAB vs VFF — Head-to-Head

Bigger by revenue
LAB
LAB
1.6× larger
LAB
$19.6M
$12.2M
VFF
Growing faster (revenue YoY)
VFF
VFF
+43.0% gap
VFF
31.5%
-11.5%
LAB
Higher net margin
VFF
VFF
197.3% more per $
VFF
19.9%
-177.4%
LAB

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
LAB
LAB
VFF
VFF
Revenue
$19.6M
$12.2M
Net Profit
$-34.7M
$2.4M
Gross Margin
48.5%
Operating Margin
-168.5%
Net Margin
-177.4%
19.9%
Revenue YoY
-11.5%
31.5%
Net Profit YoY
-28.8%
128.2%
EPS (diluted)
$-0.09
$0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
VFF
VFF
Q4 25
$12.2M
Q3 25
$19.6M
$66.7M
Q2 25
$21.8M
$59.9M
Q1 25
$40.8M
$77.1M
Q3 24
$22.1M
$54.9M
Q2 24
$22.5M
$53.6M
Q1 24
$45.5M
$78.1M
Q4 23
$28.2M
$-48.3M
Net Profit
LAB
LAB
VFF
VFF
Q4 25
$2.4M
Q3 25
$-34.7M
$10.2M
Q2 25
$-33.5M
$26.5M
Q1 25
$-26.0M
$-6.7M
Q3 24
$-26.9M
$-820.0K
Q2 24
$-45.7M
$-23.5M
Q1 24
$-32.2M
$-2.9M
Q4 23
$-19.8M
$-25.5M
Gross Margin
LAB
LAB
VFF
VFF
Q4 25
Q3 25
48.5%
47.9%
Q2 25
48.8%
37.3%
Q1 25
48.4%
14.7%
Q3 24
54.9%
24.8%
Q2 24
46.1%
25.4%
Q1 24
53.1%
19.9%
Q4 23
47.6%
Operating Margin
LAB
LAB
VFF
VFF
Q4 25
Q3 25
-168.5%
23.3%
Q2 25
-118.1%
20.8%
Q1 25
-80.8%
-8.0%
Q3 24
-120.9%
3.8%
Q2 24
-134.5%
-43.5%
Q1 24
-132.2%
-3.0%
Q4 23
-75.9%
Net Margin
LAB
LAB
VFF
VFF
Q4 25
19.9%
Q3 25
-177.4%
15.3%
Q2 25
-153.7%
44.2%
Q1 25
-63.8%
-8.7%
Q3 24
-122.0%
-1.5%
Q2 24
-203.3%
-43.9%
Q1 24
-70.6%
-3.7%
Q4 23
-70.2%
52.8%
EPS (diluted)
LAB
LAB
VFF
VFF
Q4 25
$0.01
Q3 25
$-0.09
$0.08
Q2 25
$-0.09
$0.24
Q1 25
$-0.07
$-0.06
Q3 24
$-0.07
$-0.01
Q2 24
$-0.12
$-0.21
Q1 24
$-0.27
$-0.03
Q4 23
$-0.24
$-0.24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
VFF
VFF
Cash + ST InvestmentsLiquidity on hand
$129.4M
$81.2M
Total DebtLower is stronger
$33.7M
Stockholders' EquityBook value
$399.7M
$299.9M
Total Assets
$539.6M
$423.1M
Debt / EquityLower = less leverage
0.11×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
VFF
VFF
Q4 25
$81.2M
Q3 25
$129.4M
$82.6M
Q2 25
$158.6M
$60.0M
Q1 25
$150.9M
$15.1M
Q3 24
$210.6M
$28.7M
Q2 24
$269.8M
$29.7M
Q1 24
$287.1M
$26.7M
Q4 23
$51.7M
$30.3M
Total Debt
LAB
LAB
VFF
VFF
Q4 25
$33.7M
Q3 25
$34.6M
Q2 25
$39.1M
Q1 25
$39.2M
Q3 24
$55.2M
$43.3M
Q2 24
$55.1M
$44.4M
Q1 24
$55.0M
$46.1M
Q4 23
$63.5M
$48.1M
Stockholders' Equity
LAB
LAB
VFF
VFF
Q4 25
$299.9M
Q3 25
$399.7M
$295.4M
Q2 25
$424.5M
$284.3M
Q1 25
$454.6M
$248.3M
Q3 24
$489.3M
$274.4M
Q2 24
$510.3M
$275.2M
Q1 24
$577.3M
$296.2M
Q4 23
$-148.1M
$299.6M
Total Assets
LAB
LAB
VFF
VFF
Q4 25
$423.1M
Q3 25
$539.6M
$418.4M
Q2 25
$557.0M
$403.7M
Q1 25
$579.6M
$377.1M
Q3 24
$681.5M
$417.8M
Q2 24
$708.7M
$425.4M
Q1 24
$777.7M
$458.4M
Q4 23
$323.1M
$464.0M
Debt / Equity
LAB
LAB
VFF
VFF
Q4 25
0.11×
Q3 25
0.12×
Q2 25
0.14×
Q1 25
0.16×
Q3 24
0.11×
0.16×
Q2 24
0.11×
0.16×
Q1 24
0.10×
0.16×
Q4 23
0.16×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
VFF
VFF
Operating Cash FlowLast quarter
$-22.2M
Free Cash FlowOCF − Capex
$-23.1M
FCF MarginFCF / Revenue
-118.1%
Capex IntensityCapex / Revenue
4.5%
90.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
VFF
VFF
Q4 25
Q3 25
$-22.2M
$24.4M
Q2 25
$-20.7M
Q1 25
$-30.3M
$-6.4M
Q3 24
$-27.9M
$4.3M
Q2 24
$-39.0M
$5.7M
Q1 24
$-62.5M
$-50.0K
Q4 23
$-14.1M
$-1.5M
Free Cash Flow
LAB
LAB
VFF
VFF
Q4 25
Q3 25
$-23.1M
$22.6M
Q2 25
$-22.6M
Q1 25
$-35.3M
$-8.9M
Q3 24
$-30.1M
$1.5M
Q2 24
$-41.0M
$4.8M
Q1 24
$-63.3M
$-1.9M
Q4 23
$-14.1M
$-2.2M
FCF Margin
LAB
LAB
VFF
VFF
Q4 25
Q3 25
-118.1%
33.9%
Q2 25
-103.6%
Q1 25
-86.6%
-11.6%
Q3 24
-136.4%
2.7%
Q2 24
-182.2%
9.0%
Q1 24
-138.9%
-2.5%
Q4 23
-50.2%
4.6%
Capex Intensity
LAB
LAB
VFF
VFF
Q4 25
90.8%
Q3 25
4.5%
2.7%
Q2 25
8.7%
4.6%
Q1 25
12.4%
3.3%
Q3 24
10.2%
5.1%
Q2 24
8.6%
1.6%
Q1 24
1.7%
2.4%
Q4 23
0.3%
-1.6%
Cash Conversion
LAB
LAB
VFF
VFF
Q4 25
Q3 25
2.39×
Q2 25
Q1 25
Q3 24
Q2 24
Q1 24
Q4 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

VFF
VFF

International Sales$8.7M71%
Cannabis United States Segment$3.4M27%

Related Comparisons